Gilead Sciences paid its 5 named executives $65.4M in total in FY2025 (Dec). CEO Daniel P. O’Day was paid $28.4M of that.
Pay$100 in the stock at the end of FY18 → $231
Pay of each named executive
Daniel P. O’DayChairman and Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) | ||||||
| FY2020 (Dec) | ||||||
| FY2019 (Dec) |
7 years
Dietmar BergerM.D., Ph.D. Chief Medical Officer
| FY2025 (Dec) |
1 year
Johanna MercierChief Commercial and Corporate Affairs Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) | ||||||
| FY2020 (Dec) | ||||||
| FY2019 (Dec) |
7 years
Andrew D. DickinsonChief Financial Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) | ||||||
| FY2020 (Dec) | ||||||
| FY2019 (Dec) |
7 years
Deborah H. TelmanFormer Executive Vice President, Corporate Affairs and General Counsel
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $26.1M. The CEO of Gilead Sciences was paid $28.4M, 9% above the median.
- 1Eli Lilly & Co
- 2Johnson & Johnson
- 3AbbVie
- 4Gilead SciencesThis company
- 5Pfizer
- 6Amgen
- 7Bristol Myers Squibb
- 8Merck & Co.
- 9Regeneron Pharmaceuticals
- 10BiogenNot disclosed
- 11Vertex Pharmaceuticals IncorporatedNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.